Further molecular profiling of patients with CDC and RMC in the REPRINT trial
RCC Content Hub
Giuseppe Procopio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, comments on ongoing investigations into biological samples collected in the Phase II REPRINT trial (NCT06302569) to identify genomic features that can help select patients with collecting duct carcinoma (CDC) and renal medullary carcinoma (CMC) for treatment. SMARCC2B1 deficiency is a lost tumor suppressor gene and a potential candidate for treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.